The impending medical revolution in

haemophilia care: one patient’s view by Jones, Adam
Jones, Adam (2015) The impending medical revolution in haemophilia care: one 
patient’s view. The Journal of Haemophilia Practice, 2 (1). pp. 9-11. ISSN 2055-
3390 
Downloaded from: http://sure.sunderland.ac.uk/5344/
Usage guidelines
Please  refer  to  the  usage guidelines  at  http://sure.sunderland.ac.uk/policies.html  or  alternatively 
contact sure@sunderland.ac.uk.
www.haemjournal.com
9
The Journal of Haemophilia Practice 2015; 2(1): 9-11. doi: 10.17225/jhp.00041
GENE THERAPY
Adam R Jones
purge among the haemophilia community, with lives being
lost or affected by HIV/AIDS and hepatitis C [2] through no
fault of their own. Not a day goes by that I don’t think of
my dear friends who are still struggling with, or were
unable to win the battle against these dreadful diseases,
which contaminated the UK supply of blood and blood
products [3]. I am one of the lucky few to come through
this period of devastation relatively unscathed. I don’t
know how, but to this day I remain HIV negative. Maybe I
am CCR5 Δ32 homozygous [4]? Even so, I have contracted
both hepatitis B and hepatitis C through treatment with
infected clotting factor IX (FIX), but on both occasions my
immune system has managed to clear these viruses
without the need for medical intervention (other than a
liver biopsy).
Enter the recombinants
Some years later I was elated to learn that there was a new
treatment, recombinant FIX (rFIX) [5], being made available,
The history of haemophilia care has been fraught with extreme
successes and epic failures. The development of plasma-
derived concentrates made prophylactic treatment and home
care possible, but the unintended consequences were
devastating for a generation and only abated with the
emergence of recombinant products. Now with the arrival of
longer-acting factor concentrates and the potential offered by
gene therapy, further improvements in medical and social
outcomes are possible. But these new treatment approaches
raise challenging ethical and moral issues that society must be
prepared to confront.
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I was born in April 1972. Six months later I was diagnosed
with severe haemophilia B, which at that time was more
commonly known as Christmas disease, being so named
after Stephen Christmas, the first patient in whom it was
described as being different from classical haemophilia
(which is now known as haemophilia A) [1]. During the
ensuing years I have witnessed much of the evolution of
care and treatment for haemophilia in the United
Kingdom.
I can recall the days when hospital admission seemed,
for me at least, to be the norm rather than the exception.
Many times I was placed in traction for joint bleeds –
especially knee bleeds, a practice that, as far as I am aware,
has long been abandoned. As a child I remember when it
was necessary to travel to hospital for treatment each time
I had a bleed, and hoping that I would get there before the
haemophilia unit closed so that my parents and I would
not have to wait hours for the doctor on call to arrive. It
made an incredible difference when I was allowed to begin
home treatment and my mother was trained to prepare
and administer my clotting factor.
I also remember the isolation I felt at school for being
different to everyone else; this difference being most
evident during physical education lessons where all the
other boys in my class were learning how to play football,
rugby, hockey, or cricket. In those years these were all
games in which I was never allowed to participate for fear
of injury.
The 1980s and 1990s ushered in the beginning of a
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vector is most suitable for each target illness, or vector
optimisation to reduce or eradicate insertional
mutagenesis, but the answers are beginning to come thick
and fast! There have been numerous studies over recent
years [11], the most notable of which was reported in the
New England Journal of Medicine in 2011 and was
performed by Professor Amit Nathwani and his team [12]. A
strain of virus akin to the common cold, known as adeno-
associated virus serotype 8, was genetically modified to be
the vector by which the gene for FIX was inserted into the
liver cells of severe haemophilia B patients. The results so
far are very positive and seem to be relatively long-lasting
[13]. Though none of the haemophiliacs in this study has
been completely cured of haemophilia, they are all
expressing levels of FIX in excess of 1%, which means that
they have been cured of the severe phenotype, at least for
the past three years. This is a highly significant moment,
and the world is, or rather should be, watching.
Of course this now raises a further question, one which
society may not yet be ready to discuss or even
acknowledge but which is nevertheless inescapable.
Should gene therapy prove to be a viable and affordable
treatment option (which I sincerely hope it will), the natural
progression is to ask if it is enough for it to be used merely
as a treatment strategy, much like rFIX is presently used, or
if there is the confidence, will, courage, ambition,
conviction, and hope (call it what you may), to make this
approach to treatment more than a glorified sticking
plaster. I refer now, of course, to germ-line gene therapy
[14]. I can already picture the furore erupting in ethics
committees across universities and health organisations
(not to mention anti-genetic modification campaigners) as
I write this, but this debate will happen and must happen.
Momentum for this is, in my humble opinion, building as
the evidence of gene therapy efficacy mounts.
A conundrum for the West
This leaves the rich Western economies with a
conundrum. As treatments improve and develop for
haemophiliacs living in first world economies, what will be
the fate of treatment for those living in third world
economies? Will personalised medicine in the West lead
naturally to clotting factor (plasma derived or
recombinant) becoming cheaper and more affordable for
them? Will the licensing on recombinant clotting factors
be relaxed so that it can be made available and affordable
by local generic biopharmaceutical manufacturers for the
majority of haemophiliacs worldwide who presently have
little or no access to treatment? Or will the current health
inequalities in worldwide haemophilia care and treatment
remain, or even widen [15]? These are serious questions
which we – patients, clinicians and scientists – as a
community cannot ignore; and which politicians and
industry must not avoid.
I look back over my past experiences of living with
severe haemophilia B and see how far haemophilia care
which removed the need for blood donors as the clotting
factor was produced using microorganisms. This removed
the risk of blood-borne infections ravaging the
haemophilia community once more. Realising this was like
being freed from a permanent tether to the angel of death,
and rescue from the uncertainty of if, or when, his scythe
would swing and cut me down.
Then, sometime around 2000/01 there was the setback
of potential contamination of treatments with variant
Creutzfeldt Jakob disease (vCJD) [6]. I received three
letters from two separate haemophilia units where I had
received care in the past stating that it was possible that
my FIX may have come from a blood donor who had died
from this spongiform encephalopathy. The first of these
letters came during my final year at university, right in the
middle of my dissertation!
As a result of these and other experiences, I have for
many years been keenly watching for new developments
in haemophilia treatment, and in my opinion we are on the
verge of a medical revolution. My nephew, who lives in the
USA, has been treated with a newly Food and Drug
Administration (FDA) licensed rFIX product, Alprolix™ [7, 8],
which has a much longer half-life than the rFIX we use
currently in the UK. You may think this anecdotal, but he
speaks very highly of it. It has reduced his prophylaxis
frequency, improving his compliance in administering his
rFIX; it has reduced his frequency of breakthrough
bleeding, but above all, it has provided him with an
improved quality of life. So far, so good, but even better is
the news that this long acting rFIX may soon be approved
for use by the NHS in the UK. Which makes me think how
different my life might have been had this treatment been
available to my friends and I when we were younger.
Of course it is the new generation of haemophiliacs who
will receive the lion’s share of the benefits of this promising
new treatment, such as fewer bleeds, a longer time
between injections, improved social, educational,
employment and sporting activity participation, along with
a hopefully reduced likelihood of developing the classical
haemophilic joint arthropathies [9] of the ankles, knees and
elbows. I am thrilled to know that my daughter, who is a
low-level carrier, has a future that is brighter and more
optimistic than my past.
More radical treatments
Even though the immediate future is full of promise from
the prospect of long-acting rFIX, there are signs that more
radical treatments may soon bear fruit. This is the potential
medical revolution I was referring to earlier. I am speaking
of gene therapy. Do not be deterred by the nay-sayers, but
neither let yourself be swept up by the folly of a silver
bullet. gene therapy, in principle, works, the evidence is
clear [10]. What is not yet clear is whether or not it is
permanent, whether or not it can produce repeatable
outcomes, and whether or not it will work in everyone.
There is still much to learn about things such as which
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part go untreated [15]. As we hail improved medical and
social outcomes through rising standards and efficacy in
treatments we must not neglect the needs of those who
lack these advantages purely on the basis of the political
landscape and geographical location in which they were
born and now live. As science and medicine advances
towards a more personalised nature, we must not allow
ourselves to become so overawed that we forget our
humanity.
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has come in my lifetime. With it, I also see the price the
haemophilia community has paid to get here, and the
price many are still paying. The legacy that will be left to
future generations of haemophiliacs worldwide should be
one of hope founded in evidence, if only for the sake of
those who have fallen and thus helped to shape the path
which has brought us to this point. This is a legacy which I
never dreamed would be possible in my lifetime, but the
evidence shows that it is steadily becoming an inevitable
reality.
A plea for humanity
The successes of gene therapy trials in haemophilia to date
leave me sitting on the edge of my seat in anticipation.
Until gene therapy comes of age as a licensed and
affordable mainstream treatment, the advances being
concurrently made in the area of longer-acting clotting
factors continues to raise the hopes and expectations of all
those who rely on these medications to sustain life. 
Haemophilia, it should be remembered, is not just a first-
world illness. Its effects are felt globally, and for the most
